M344 and Its Effect on BRCA1 in Breast and Ovarian Cancer Cells
Author Information
Author(s): Johanne I Weberpals, Anna M O'Brien, Nima Niknejad, Kyla D Garbuio, Katherine V Clark-Knowles, Jim Dimitroulakos
Primary Institution: The Ottawa Hospital
Hypothesis
The histone deacetylase inhibitor M344 can inhibit BRCA1 expression and enhance the sensitivity of breast and ovarian cancer cells to cisplatin.
Conclusion
M344 enhances the sensitivity of breast and ovarian cancer cells to cisplatin by reducing BRCA1 expression.
Supporting Evidence
- M344 treatment led to a significant decrease in BRCA1 mRNA and protein levels.
- Combination treatment with M344 and cisplatin resulted in increased cytotoxicity in breast and ovarian cancer cells.
- The study demonstrated that M344 enhances cisplatin-induced DNA damage as indicated by increased γH2A.X foci.
Takeaway
This study shows that a drug called M344 can help make cancer cells more sensitive to a common chemotherapy drug by lowering the levels of a protein called BRCA1.
Methodology
The study involved treating various breast and ovarian cancer cell lines with M344 and cisplatin, followed by assessments of BRCA1 expression and cell viability.
Limitations
The study was conducted in cancer cell lines, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website